Olivier Hermine
Professor of Hematology
Hopital Necker / Universite Paris Cite · Paris, France
Renowned French hematologist and member of the French Academy of Sciences. Key contributor to European MCL Network trials and MCL biology research.
Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group.
Blood advances · Jan 13, 2026
Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020.
Haematologica · Oct 30, 2025
How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives.
Bone marrow transplantation · Jun 1, 2025
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study.
Blood cancer journal · Apr 24, 2025
Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network.
British journal of haematology · Jan 1, 2025
Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials.
Leukemia · Dec 1, 2024
Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry.
Haematologica · Nov 1, 2024
Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma.
Blood · Jul 18, 2024
Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Mar 1, 2024